[
    {
        "headline": "Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings",
        "text": "Revvity, Inc. ( NYSE:RVTY ) just reported healthy earnings but the stock price didn't move much. Investors are probably..."
    },
    {
        "headline": "Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know",
        "text": "A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains."
    },
    {
        "headline": "RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine",
        "text": "Life sciences company Revvity (NYSE:RVTY) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.01 per share was 6.4% above analysts’ consensus estimates."
    },
    {
        "headline": "3 S&P 500 Stocks in the Doghouse",
        "text": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition."
    },
    {
        "headline": "1 Safe-and-Steady Stock with Exciting Potential and 2 to Avoid",
        "text": "Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies."
    },
    {
        "headline": "Revvity to Present at Upcoming Investor Conferences",
        "text": "WALTHAM, Mass., April 30, 2025--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:"
    },
    {
        "headline": "Mettler-Toledo (MTD) Q1 Earnings: What To Expect",
        "text": "Precision measurement company Mettler-Toledo (NYSE:MTD) will be announcing earnings results tomorrow after market hours. Here’s what investors should know."
    },
    {
        "headline": "Revvity First Quarter 2025 Earnings: EPS Beats Expectations",
        "text": "Revvity ( NYSE:RVTY ) First Quarter 2025 Results Key Financial Results Revenue: US$664.8m (up 2.3% from 1Q 2024). Net..."
    },
    {
        "headline": "Company News for Apr 29, 2025",
        "text": "Companies In The News Are: DPZ, RVTY, OPRA, INMD."
    },
    {
        "headline": "Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ...",
        "text": "Revvity Inc (RVTY) reports a robust Q1 2025 performance, exceeding EPS expectations and demonstrating resilience amidst macroeconomic challenges."
    },
    {
        "headline": "Q1 2025 Revvity Inc Earnings Call",
        "text": "Q1 2025 Revvity Inc Earnings Call"
    },
    {
        "headline": "RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up",
        "text": "Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales."
    },
    {
        "headline": "Biotech Firm Revvity Reports Better-Than-Expected Earnings",
        "text": "Revvity reported first-quarter earnings that topped analysts' estimates."
    },
    {
        "headline": "Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates",
        "text": "While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values."
    },
    {
        "headline": "Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook",
        "text": "(Reuters) -Medical equipment maker Revvity on Monday joined larger peers in warning about the impact of tariffs imposed by the U.S. President Donald Trump's administration, but maintained its annual profit outlook. Revvity anticipates a $135 million impact from tariffs on China; however, plans cost-saving measures and expects to benefit from a weaker dollar due to generating more than half its revenue outside the U.S. The warnings came after Revvity posted first-quarter results above Wall Street estimates on steady demand for tools used in medical research."
    },
    {
        "headline": "Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates",
        "text": "Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?"
    },
    {
        "headline": "Revvity: Q1 Earnings Snapshot",
        "text": "WALTHAM, Mass. AP) — Revvity, Inc. RVTY) on Monday reported first-quarter earnings of $42.2 million."
    },
    {
        "headline": "Revvity (NYSE:RVTY) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations",
        "text": "Life sciences company Revvity (NYSE:RVTY) announced better-than-expected revenue in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.01 per share was 6.4% above analysts’ consensus estimates."
    },
    {
        "headline": "Revvity Announces Financial Results for the First Quarter of 2025",
        "text": "WALTHAM, Mass., April 28, 2025--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025."
    },
    {
        "headline": "Revvity (RVTY) Q1 Earnings Report Preview: What To Look For",
        "text": "Life sciences company Revvity (NYSE:RVTY) will be reporting results tomorrow before market hours. Here’s what investors should know."
    },
    {
        "headline": "Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings",
        "text": "Revvity, Inc. ( NYSE:RVTY ) just reported healthy earnings but the stock price didn't move much. Investors are probably..."
    },
    {
        "headline": "Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know",
        "text": "A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains."
    },
    {
        "headline": "RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine",
        "text": "Life sciences company Revvity (NYSE:RVTY) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.01 per share was 6.4% above analysts’ consensus estimates."
    },
    {
        "headline": "3 S&P 500 Stocks in the Doghouse",
        "text": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition."
    },
    {
        "headline": "1 Safe-and-Steady Stock with Exciting Potential and 2 to Avoid",
        "text": "Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies."
    },
    {
        "headline": "Revvity to Present at Upcoming Investor Conferences",
        "text": "WALTHAM, Mass., April 30, 2025--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:"
    },
    {
        "headline": "Mettler-Toledo (MTD) Q1 Earnings: What To Expect",
        "text": "Precision measurement company Mettler-Toledo (NYSE:MTD) will be announcing earnings results tomorrow after market hours. Here’s what investors should know."
    },
    {
        "headline": "Revvity First Quarter 2025 Earnings: EPS Beats Expectations",
        "text": "Revvity ( NYSE:RVTY ) First Quarter 2025 Results Key Financial Results Revenue: US$664.8m (up 2.3% from 1Q 2024). Net..."
    },
    {
        "headline": "Company News for Apr 29, 2025",
        "text": "Companies In The News Are: DPZ, RVTY, OPRA, INMD."
    },
    {
        "headline": "Revvity Inc (RVTY) Q1 2025 Earnings Call Highlights: Surpassing Expectations with Strong ...",
        "text": "Revvity Inc (RVTY) reports a robust Q1 2025 performance, exceeding EPS expectations and demonstrating resilience amidst macroeconomic challenges."
    },
    {
        "headline": "Q1 2025 Revvity Inc Earnings Call",
        "text": "Q1 2025 Revvity Inc Earnings Call"
    },
    {
        "headline": "RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up",
        "text": "Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales."
    },
    {
        "headline": "Biotech Firm Revvity Reports Better-Than-Expected Earnings",
        "text": "Revvity reported first-quarter earnings that topped analysts' estimates."
    },
    {
        "headline": "Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates",
        "text": "While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values."
    },
    {
        "headline": "Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook",
        "text": "(Reuters) -Medical equipment maker Revvity on Monday joined larger peers in warning about the impact of tariffs imposed by the U.S. President Donald Trump's administration, but maintained its annual profit outlook. Revvity anticipates a $135 million impact from tariffs on China; however, plans cost-saving measures and expects to benefit from a weaker dollar due to generating more than half its revenue outside the U.S. The warnings came after Revvity posted first-quarter results above Wall Street estimates on steady demand for tools used in medical research."
    },
    {
        "headline": "Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates",
        "text": "Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?"
    },
    {
        "headline": "Revvity: Q1 Earnings Snapshot",
        "text": "WALTHAM, Mass. AP) — Revvity, Inc. RVTY) on Monday reported first-quarter earnings of $42.2 million."
    },
    {
        "headline": "Revvity (NYSE:RVTY) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations",
        "text": "Life sciences company Revvity (NYSE:RVTY) announced better-than-expected revenue in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.01 per share was 6.4% above analysts’ consensus estimates."
    },
    {
        "headline": "Revvity Announces Financial Results for the First Quarter of 2025",
        "text": "WALTHAM, Mass., April 28, 2025--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025."
    },
    {
        "headline": "Revvity (RVTY) Q1 Earnings Report Preview: What To Look For",
        "text": "Life sciences company Revvity (NYSE:RVTY) will be reporting results tomorrow before market hours. Here’s what investors should know."
    },
    {
        "headline": "Why Revvity (RVTY) Could Beat Earnings Estimates Again",
        "text": "Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report."
    },
    {
        "headline": "Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?",
        "text": "RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China."
    },
    {
        "headline": "Revvity Board Declares Quarterly Dividend",
        "text": "WALTHAM, Mass., April 24, 2025--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025."
    },
    {
        "headline": "Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for",
        "text": "Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."
    },
    {
        "headline": "3 Cash-Producing Stocks Skating on Thin Ice",
        "text": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand."
    },
    {
        "headline": "Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline",
        "text": "Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."
    },
    {
        "headline": "What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing?",
        "text": "Revvity, Inc. ( NYSE:RVTY ) saw significant share price movement during recent months on the NYSE, rising to highs of..."
    },
    {
        "headline": "Revvity to Hold Earnings Call on Monday, April 28, 2025",
        "text": "WALTHAM, Mass., April 03, 2025--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call."
    },
    {
        "headline": "FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo",
        "text": "The World Health Organization recognises the test as the “only” enzyme-linked immunospot-based interferon-gamma release assay."
    },
    {
        "headline": "Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test",
        "text": "WALTHAM, Mass., April 02, 2025--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-"
    },
    {
        "headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
        "text": "RVTY's strong product portfolio raises optimism about the stock."
    },
    {
        "headline": "1 Healthcare Stock to Target This Week and 2 to Turn Down",
        "text": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline."
    },
    {
        "headline": "The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years",
        "text": "If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to..."
    },
    {
        "headline": "Revvity Stock Tumbles Despite Expanding Genomics England Alliance",
        "text": "RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes."
    },
    {
        "headline": "Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England",
        "text": "WALTHAM, Mass., March 20, 2025--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services."
    }
]